Zhang G, et al. - Researchers comprehensively estimated and evaluated the clinical utility of prostate health index (PHI) as a diagnostic tool for prostate cancer, by analyzing 20 eligible studies including 5543 subjects. The sensitivity and specificity were estimated to be 0.75 and 0.69, respectively. The estimated pooled area under the curve was 0.78. The combined positive likelihood ratio and the negative likelihood ratio were 2.45 and 0.36, respectively. Findings revealed a moderate diagnostic accuracy of the PHI in diagnosing prostate cancer. The PHI displayed a discrimination ability that was slightly prior to free/total prostate-specific antigen. Compared to the Caucasian population setting, a slightly higher diagnostic accuracy of PHI was evident in the Asian population setting.